Literature DB >> 4082241

Plasma flupentixol concentrations and clinical response in acute schizophrenia.

A E Balant-Gorgia, R Eisele, J M Aeschlimann, L P Balant, G Garrone.   

Abstract

Twenty-three acutely psychotic inpatients treated with flupentixol were included in the study. Steady-state plasma concentrations were compared with therapeutic outcome in a routine clinical setting. The threshold concentration for satisfactory antipsychotic effect appeared to be approximately 2 ng/ml. Controlled studies are needed to establish the existence and exact limits of a therapeutic window.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082241     DOI: 10.1097/00007691-198512000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Flupentixol: relevance of stereoselective therapeutic drug monitoring.

Authors:  Pierre Baumann; Hartmut Kirchherr; Patricia Berney; Christoph Hiemke
Journal:  Psychopharmacology (Berl)       Date:  2012-04-04       Impact factor: 4.530

Review 2.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

3.  Stereoselective disposition of flupentixol: influence on steady-state plasma concentrations in schizophrenic patients.

Authors:  A E Balant-Gorgia; L P Balant; M Gex-Fabry; C Genet
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

4.  Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.

Authors:  K Kistrup; J Gerlach; T Aaes-Jørgensen; N E Larsen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature.

Authors:  Loren Bailey; David Taylor
Journal:  Psychopharmacology (Berl)       Date:  2019-07-12       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.